GILD - Gilead Sciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

GILD

GILEAD SCIENCES, INC.

NASDAQ

$146.34

▲ UP 0.45% (0.66)

KEY STATISTICS

Market Cap$181.69 B

52w High$157.29

52w Low$108.46

Dividend Yield2.48%

FrequencyQuarterly

P/E-375.23

Volume6.51M

Shares Out.1.24B

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Daniel O'Day

COMPENSATION 2026

Salary$1,795,192

Stock Awards$15,238,402

Incentive Plan Pay$4,848,120

All Other Comp.$2,055,424

Total$28,437,198

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 22, 1992

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

17,000

PRICE TARGET

Target High$180.00

Target Low$123.00

Target Median$152.50

Target Consensus$151.25

UPCOMING EARNINGS

DateOct 29, 2026

DayThursday

Rev. Est.$7.78B

OCT

THU

SPLIT RECORD

DATE	TYPE	RATIO
2013-01-28	Forward	2:1
2007-06-25	Forward	2:1
2004-09-07	Forward	2:1
2002-03-08	Forward	2:1
2001-02-22	Forward	2:1

PRICE

$146.34 ▲ UP 0.45% (+$0.66)

OVERLAYS

About Gilead Sciences, Inc.

https://www.gilead.com ↗

Gilead Sciences is a biopharma company developing medicines for HIV/AIDS, COVID-19, liver diseases, cancer, and other conditions, with global collaborations and a diverse product portfolio.

INDUSTRY

Drug Manufacturers - General

A PRODUCT GILEAD SCIENCES, INC. IS KNOWN FOR

Yeztugo (lenacapavir)

Yeztugo, Gilead's twice-yearly injectable PrEP, offers a groundbreaking, infrequent-dosing HIV prevention option designed to improve adherence and expand the PrEP market.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q3-2025	Q4-2025	Q1-2026	Q2-2026
Total HIV	—	—	—	$5.69B
Products Other HIV	$5.28B	$5.8B ▲	$5.03B ▼	—
Total Liver Disease	—	—	—	$877M
Total Oncology	—	—	—	$873M
Cell Therapy Products Total Cell Therapy Product Sales	$515M	$627M ▲	$482M ▼	—
Trodelvy	$357M	$383M ▲	$402M ▲	—
Other Products Total Other product sales	$184M	$204M ▲	$196M ▼	—
Royalty contract and other revenues	—	—	—	$176M
Total Other	—	—	—	$161M
Veklury	$277M	$211M ▼	$144M ▼	$23M ▼